Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia
Author:
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2001.03143.x/fullpdf
Reference12 articles.
1. Consensus resolution: Proposed criteria for evaluation of response to treatment in hairy cell leukemia;Catovsky;Leukemia,1987
2. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of The National Cancer Institute: a report of 979 patients;Cheson;Journal of Clinical Oncology,1998
3. Chimaeric monoclonal anti-CD20 antibody (rituximab) - an effective treatment for a patient with relapsing hairy cell leukemia;Hagberg;Medical Oncology,1999
4. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine;Hoffman;British Journal of Haematology,2000
5. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia after treatment with 2- chlorodeoxyadenosine;Juliusson;Blood,1994
Cited by 102 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group;Cancers;2024-06-10
2. Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia;Blood Advances;2023-11-03
3. Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials;Expert Opinion on Investigational Drugs;2023-03-23
4. Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond Cladribine;Cancers;2022-02-15
5. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues;Blood Reviews;2022-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3